title: Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
abstract: The neonatal Fc receptor (FcRn) is a key determinant of IgG homeostasis. It binds to the Fc domain of IgG in a strictly pH-dependent manner and protects IgG from lysosomal degradation. The impact of FcRn salvage pathway on IgG monoclonal antibody (mAb) pharmacokinetics (PK) has been well established. In this report, a set of mAbs with wild-type human Fc sequences but different Fab domains were used to examine the potential impact of Fab domain on in vitro FcRn binding and in vivo PK. We were surprised to find that mAbs with the same wild-type human Fc sequences but different Fab domains were shown to bind FcRn with considerable differences in both the binding at acidic pH and the dissociation at neutral pH, suggesting that the Fab domain may also have an impact on FcRn interaction. For these mAbs, no relationship between the FcRn binding affinity at acidic pH and in vivo PK was found. Instead, an apparent correlation between the in vitro FcRn dissociation at neutral pH and the in vivo PK in human FcRn mice, nonhuman primates and humans was observed. Our results suggested that the Fab domain of mAbs can affect their interaction with FcRn and thus their pharmacokinetic properties and that in vitro FcRn binding/dissociation assays can be a useful screening tool for pharmacokinetic assessment of mAbs with wild-type Fc sequences.
authors: Department of Drug Metabolism and Pharmacokinetics, Merck Sharp and Dohme Corp., West Point, PA 19486, USA. weirong_wang@merck.com
authors: Weirong
authors: W
authors: Wang
authors: Ping
authors: P
authors: Lu
authors: Yulin
authors: Y
authors: Fang
authors: Lora
authors: L
authors: Hamuro
authors: Tamara
authors: T
authors: Pittman
authors: Brian
authors: B
authors: Carr
authors: Jerome
authors: J
authors: Hochman
authors: Thomayant
authors: T
authors: Prueksaritanont